Cell & Gene Therapy Manufacturing Services Market To Generate Revenue Worth $20,164 Million by 2030

The global cell & gene therapy manufacturing services market is projected to generate USD 20,164 million revenue by 2030, advancing at a CAGR of 18.60% during 2022–2030. This can be ascribed to the high incidence of cancer and other target diseases, the increasing pharmaceutical R&D spending, and the rising private and public investments in the cell and gene therapy industry.

Big pharmaceutical businesses are determined to de-risk R&D exertions and improve the speed to develop and market their life-changing medications, along with minimizing their production costs. The rising number of biotech and specialty companies are relying on service providers to evade the high costs of in-house manufacturing, development, and expertise essential to produce their molecules through clinical development. The growing complexity of new molecular entities (NMEs) development has created a demand for niche competencies and capabilities that pharmaceutical organizations desire to access externally rather than include in-house.

Globally, the rising prevalence of chronic diseases is one of the major healthcare burdens, which affects high-income as well as low- and middle-income countries. The incidence of major chronic diseases, such as coronary artery disease, diabetes, chronic obstructive pulmonary disease (COPD), asthma, arthritis, hepatitis, and cancer, has increased significantly across the globe. This is due to the escalating geriatric population, changing lifestyles, and dietary changes as a result of rapid urbanization. Thus, these factors drive the demand for therapy manufacturing services.

Cardiovascular Disease Category To Witness the Fastest Growth

The cardiovascular disease category is expected to grow at the highest CAGR, of around 19%, during the forecast period, owing to the increasing cases of cardiovascular diseases (CVDs) across the world. A major public health concern is physical inactivity, which is also accompanied by the increased risk of morbidity or worsening of many chronic diseases and health conditions. Some of these problems include CVD, stroke, congestive heart failure, and others.

Numerous studies have proved that excess television (TV) viewing time, independent from overall physical activity levels, is adversely associated with metabolic risk factors. The effects of extended periods of sedentary behavior are to be characterized by metabolic alterations, which are frequently seen in atherosclerotic and diabetogenic profiles.

Geographically, APAC holds a significant share of the market. This is due to a massive and rapidly rising population, which is demanding improved access to medicines; and the increasing affordability of pharmaceuticals, as a result of the emergence of low-cost generics. Additionally, an increase in GDP per capita, a surge in the number of government healthcare programs, and a rise in the urbanization rate have expanded access to doctors and pharmacies for significant portions of the population. This offers several opportunities to manufacturers of cell & gene therapies.

In addition, the market in LATAM is primarily driven by the increasing number of hospitals performing gene therapy for cancer patients and the surging geriatric population in the region. For instance, at present, a number of hospitals in Mexico, including Hospital San Jose Tec De Monterrey, San Javier Hospital, International Bio Care Hospital, San Javier Marina Hospital, San Angel Hospital, and Hospital Médica Sur, are performing cell & gene therapies to cure cancer patients.

The major players operating in the cell & gene therapy manufacturing services market include Lonza Group Ltd., Catalent Inc., Thermo Fisher Scientific, Charles River Laboratories International Inc., WuXi AppTec, Merck KGaA, Takara Bio Inc., Nikon CeLL innovation Co. Ltd., FUJIFILM Diosynth Biotechnologies U.S.A. Inc., and Oxford Biomedica plc.